Physician profile
Larry E Patterson
NPI 1851394241
$57,197.58
in general payments reported to CMS, 2019-2025
31 companies · $790 in 2025
The $790 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $45K · 2020: $338 · 2021: $464 · 2022: $8,213 · 2023: $1,353 · 2024: $765 · 2025: $790.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,217 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $691.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,217.18 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $691.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Omeros Corporation | $44,047.09 | 2019-2021 | |
| Rayner Intraocular Lenses Limited | $8,525.44 | 2022-2025 | Omidria, Omidria, Rayone Aspheric |
| Glaukos Corporation | $847.41 | 2019-2025 | Idosetr, Photrexa Viscous and Photrexa |
| Abbvie INC. | $664.39 | 2022-2025 | |
| Bausch & Lomb Americas INC. | $467.82 | 2022-2025 | Envista Mx60 Iol, Ic-8 Apthera Iol, Scoutpro Osmolarity System |
| Apellis Pharmaceuticals, INC. | $334.41 | 2023-2025 | Syfovre |
| Alcon Vision LLC | $305.17 | 2019-2024 | Rocklatan |
| Johnson & Johnson Surgical Vision, INC. | $288.83 | 2019-2025 | Tecnis Iol |
| Genentech USA, INC. | $277.76 | 2023-2025 | Vabysmo |
| Ivantis, INC | $191.76 | 2019-2021 | |
| Allergan, INC. | $165.53 | 2020-2022 | |
| Harrow Eye, LLC | $152.38 | 2023-2025 | Iheezo |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $145.77 | 2020-2021 | |
| Carl Zeiss Meditec USA, INC. | $108.16 | 2021 | |
| New World Medical,INC. | $91.28 | 2020-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $89.42 | 2019-2025 | Eylea Hd, Eylea |
| Mallinckrodt Hospital Products INC. | $89.14 | 2021-2022 | |
| Carl Zeiss Meditec, INC. | $57.55 | 2019 | |
| Sun Pharmaceutical Industries INC. | $54.16 | 2021-2023 | Cequa |
| Novartis Pharmaceuticals Corporation | $48.65 | 2019-2020 | |
| Biotissue Holdings INC. | $44.81 | 2019-2024 | |
| Iridex Corporation | $32.52 | 2020-2022 | |
| Eyepoint US, INC. | $27.96 | 2019 | |
| Sight Sciences, INC. | $27.03 | 2021 | |
| Alimera Sciences, INC. | $21.79 | 2022 | |
| Dompe US, INC. | $21.43 | 2019 | |
| Biogen, INC. | $17.70 | 2023 | |
| Oyster Point Pharma, INC. | $15.33 | 2022 | |
| Lombart Brothers, INC. | $12.91 | 2019 | |
| Rxsight INC | $12.01 | 2022 | |
| Ocular Therapeutix, INC. | $11.97 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Larry Patterson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.